비교리스트

 카트 문의
시장보고서
상품코드
1575048

세계의 두개내 치료제 전달 시장 : 치료법별, 적응증별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2024-2032년)

Intracranial Therapeutic Delivery Market, By Therapy, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 288 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

두개내 치료제 전달 시장 규모는 2023년 19억 8,032만 달러로 평가되었고, 2024년부터 2032년까지 연평균 7.99%의 성장률을 나타낼 것으로 예상됩니다.

이 분야의 혁신은 약물의 정확한 표적화, 서방형, 생체 이용률 향상을 통해 환자의 치료 결과를 개선하는 것을 목표로 합니다. 연구의 발전과 함께 신경용 유전자 치료제 및 생물학적 제제 시장 개척도 진행되고 있습니다. 신경 질환의 유병률 증가와 의료 기술의 발전은 이 분야 수요를 촉진하는 주요 요인으로, 현대 의료에서 중요한 관심 분야로 부상하고 있습니다.

두개 내 치료제 전달 시장 - 시장 역학

신경질환의 유병률 증가로 표적치료에 대한 수요 증가

신경 질환의 유병률 증가는 두개 내 치료제 전달 시장의 중요한 촉진요인입니다. 인구 고령화와 함께 알츠하이머병, 파킨슨병, 다발성 경화증과 같은 질병은 점점 더 흔해지고 있으며, CDC에 따르면 2020년에는 미국 성인 6명 중 1명이 신경계 질환을 앓고 있는 것으로 보고되고 있습니다. 이러한 유병률 증가로 인해, 보다 효과적이고 효과적인 치료를 제공할 수 있는 혁신적인 치료제 전달 시스템에 대한 수요가 증가하고 있습니다.

또한, 인지도가 높아지고 조기 진단이 가능해지면서 전문 치료를 찾는 환자가 증가하고 있습니다. 의료 시스템이 이러한 문제를 해결하기 위해 노력하는 가운데, 새로운 두개 내 전달 방법의 연구개발에 대한 투자가 확대되어 시장 성장의 기회를 창출할 것으로 예상됩니다.

두개내 치료제 전달 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032) 동안 연평균 약 7.99%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

치료법별로는 유전자 치료가 2023년에 가장 높은 시장 점유율을 보였습니다.

적응증별로는 다발성 경화증이 2023년 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년 매출을 주도할 것으로 예상됩니다.

두개내 치료제 전달 시장-세분화 분석 :

두개 내 치료제 전달 세계 시장은 치료법, 적응증 및 지역에 따라 세분화됩니다.

시장은 치료법에 따라 세포치료, 유전자치료, 효소대체요법 등 세 가지 범주로 나뉩니다. 유전자 치료는 두개 내 치료제 전달 시장에서 가장 두드러집니다. 이 접근법은 신경 질환의 근본적인 유전적 원인을 다룰 수 있는 가능성을 제공하며, 단순한 대증요법이 아닌 장기적인 해결책을 제공합니다. 벡터 기술과 CRISPR 유전자 편집 기술의 발전으로 유전자 치료의 효능과 안전성이 향상되어 유전성 간질 및 신경 퇴행성 질환과 같은 질병에 대한 효능이 증가하고 있습니다. 개인 맞춤형 의료에 대한 관심이 높아짐에 따라 개인별 유전자 프로파일에 맞는 치료가 가능해지면서 유전자 치료에 대한 수요가 더욱 증가하고 있습니다. 전반적으로 유전자 치료의 혁신적 특성과 변화의 가능성은 유전자 치료를 시장의 주요 부문으로 자리매김하고 있습니다.

시장은 적응증에 따라 척수성 근위축증(SMA), 다발성 경화증, 배튼병, 근위축성 측색경화증 등 4가지 범주로 나뉩니다. 다발성 경화증(MS)은 두개내 치료제 전달 시장에서 가장 두드러진 분야로, 전 세계적으로 수백만 명이 앓고 있으며, 복잡한 증상을 관리하고 질병의 진행을 늦출 수 있는 혁신적인 치료 옵션에 대한 수요가 높습니다. 단클론 항체 및 경구 치료와 같은 치료법의 발전은 환자의 예후를 개선하고 시장 성장을 가속하고 있으며, MS의 유병률 증가는 보다 효과적인 치료법 연구와 함께 치료법 개발의 초점으로 MS의 중요성을 강조하고 있습니다. 인식과 진단이 개선됨에 따라 MS 관련 치료 시장은 계속 확대되고 있으며, 지배적 인 부문으로 자리 매김하고 있습니다.

두개내 치료제 전달 시장 - 지리적 통찰력

북미는 두개내 치료제 전달 시장에서 가장 규모가 큰 지역으로, 주요 헬스케어 기업의 존재, 첨단 연구시설, 탄탄한 규제 프레임워크 등이 주요 요인으로 작용하고 있습니다. 특히 미국은 높은 의료비 지출, 기술 혁신에 대한 관심, 신경 질환에 취약한 고령화 추세로 인해 높은 점유율을 차지하고 있습니다. 또한, 유리한 상환 정책과 잘 구축된 임상시험 인프라가 시장 성장을 뒷받침하고 있습니다.

이 지역에서는 신경학 연구에 대한 투자가 증가하면서 새로운 치료법 개발이 촉진되고 있습니다. 유럽과 아시아태평양은 수요가 증가하고 있는 신흥 시장이지만, 북미는 기존 헬스케어 생태계가 잘 구축되어 있어 두개내 치료제 전달을 혁신하려는 기존 기업과 신규 시장 진출기업 모두에게 초점을 맞추었습니다.

두개내 치료제 전달 시장 - 경쟁 구도 :

두개내 치료제 전달 시장은 기존 기업들과 신생 바이오테크 기업들 간의 치열한 경쟁이 특징이며, Medtronic과 AbbVie와 같은 주요 기업들은 첨단 약물 전달 시스템과 신경 질환에 대한 혁신적인 치료법에 초점을 맞추고 광범위한 제품 포트폴리오와 탄탄한 연구 개발 역량을 바탕으로 압도적인 우위를 점하고 있습니다. 연구개발력으로 압도적인 강점을 보이고 있습니다. 또한, 스트라이커와 보스턴 사이언티픽은 수술용 기기 분야에서 강력한 존재감을 발휘하며 치료 성과를 높이고 있습니다.

NeuroRx와 Zynerba Pharmaceuticals와 같은 신생 기업들은 카나비노이드 기반 치료제와 같은 새로운 치료법을 도입하여 시장 전망을 다양화하고 있습니다. 혁신을 가속화하고 시장 범위를 확대하고자 하는 기업들에게 제휴와 전략적 파트너십은 흔한 일입니다. 규제 이슈와 임상 검증의 필요성은 여전히 중요한 장애물이며 경쟁 전략에 영향을 미치고 있습니다. 전반적으로 기술 발전과 신경질환에 대한 깊은 이해가 신제품 개발의 원동력이 되고 있으며, 시장은 성장할 준비가 되어 있습니다.

목차

제1장 두개내 치료제 전달 시장 개요

  • 조사 범위
  • 시장 추정년도

제2장 주요 요약

  • 시장 내역
  • 경쟁 인사이트

제3장 두개내 치료제 전달 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장 향후 동향

제4장 두개내 치료제 전달 산업 연구

  • PEST 분석
  • Porter의 Five Forces 분석
  • 성장 전망 매핑
  • 규제 구조 분석

제5장 두개내 치료제 전달 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 두개내 치료제 전달 시장 구도

  • 두개내 치료제 전달 시장 점유율 분석, 2023년
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신규 기업 분석

제7장 두개내 치료제 전달 시장-치료법별

  • 개요
    • 치료법별 부문 점유율 분석
    • 세포 기반 치료
    • 유전자 치료
    • 효소 보충 요법

제8장 두개내 치료제 전달 시장-적응증별

  • 개요
    • 적응증별 부문 점유율 분석
    • 척수성 근위축증(SMA)
    • 다발성 경화증
    • 바텐병
    • 루게릭병
    • 기타

제9장 두개내 치료제 전달 시장-지역별

  • 서론
  • 북미
    • 개요
    • 북미 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제10장 주요 벤더 분석 - 두개내 치료제 전달 업계

  • 경쟁 대시보드
  • 기업 개요
    • Medtronic
    • AbbVie
    • Stryker Corporation
    • Baxter International
    • Ipsen SA
    • Johnson &Johnson(Ethicon)
    • NuVasive
    • NeuroRx
    • CureVac AG
    • Boston Scientific
    • Aesculap
    • Zynerba Pharmaceuticals
    • Elekta
    • Intra-Cellular Therapies

제11장 애널리스트의 전방위 전망

LSH 24.11.08

REPORT HIGHLIGHT

Intracranial Therapeutic Delivery Market size was valued at USD 1,980.32 Million in 2023, expanding at a CAGR of 7.99% from 2024 to 2032.

The intracranial therapeutic delivery market focuses on methods and technologies used to administer treatments directly into the cranial cavity, targeting conditions such as brain tumors, epilepsy, and neurodegenerative disorders. This market encompasses a variety of delivery systems, including implantable devices, infusions, and drug-eluting technologies that optimize therapeutic efficacy and minimize side effects.

Innovations in this field aim to improve patient outcomes through precise targeting, sustained release, and enhanced bioavailability of medications. As research progresses, the market is also seeing developments in gene therapy and biologics for neurological applications. The growing prevalence of neurological disorders and advances in medical technology are key factors driving demand in this sector, making it a critical area of focus in modern healthcare.

Intracranial Therapeutic Delivery Market- Market Dynamics

Increased prevalence of neurological disorders driving demand for targeted therapies.

The increasing prevalence of neurological disorders is a significant driver for the intracranial therapeutic delivery market. As the population ages, conditions such as Alzheimer's, Parkinson's, and multiple sclerosis are becoming more common, necessitating advanced treatment options. According to the CDC, an estimated 1 in 6 adults in the U.S. reported having a neurological condition in 2020. This rising incidence fuels the demand for innovative therapeutic delivery systems that can provide targeted and effective treatments.

Furthermore, greater awareness and early diagnosis contribute to the growing patient pool seeking specialized care. As healthcare systems strive to address these challenges, investments in research and development for novel intracranial delivery methods are expected to expand, creating opportunities for market growth.

Intracranial Therapeutic Delivery Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.99% over the forecast period (2024-2032)

Based on Therapy segmentation, Gene Therapy, was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Multiple Sclerosis was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Intracranial Therapeutic Delivery Market- Segmentation Analysis:

The Global Intracranial Therapeutic Delivery Market is segmented based on Therapy, Indication, and Region.

The market is divided into three categories based on Therapy: Cell-based Therapy, Gene Therapy, and Enzyme Replacement Therapy. Gene Therapy is the most prominent in the intracranial therapeutic delivery market. This approach offers the potential to address the underlying genetic causes of neurological disorders, providing long-term solutions rather than just symptomatic relief. Advances in vector technology and CRISPR gene editing are enhancing the efficacy and safety of gene therapies, making them increasingly viable for conditions like genetic forms of epilepsy and neurodegenerative diseases. The growing focus on personalized medicine further propels the demand for gene therapy, as treatments can be tailored to individual genetic profiles. Overall, its innovative nature and transformative potential position gene therapy as a leading segment in the market.

The market is divided into four categories based on Indication: Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Batten Disease, and Amyotrophic Lateral Sclerosis. Multiple Sclerosis (MS) is the most prominent in the intracranial therapeutic delivery market. MS affects millions globally, leading to significant demand for innovative treatment options that can manage its complex symptoms and slow disease progression. Advances in therapies, including monoclonal antibodies and oral treatments, are enhancing patient outcomes and driving market growth. The increasing prevalence of MS, along with ongoing research into more effective delivery methods, underscores its importance as a focal point for therapeutic development. As awareness and diagnosis improve, the market for MS-related treatments continues to expand, solidifying its position as a dominant segment.

Intracranial Therapeutic Delivery Market- Geographical Insights

North America stands out as the largest region in the intracranial therapeutic delivery market, driven primarily by the presence of leading healthcare companies, advanced research facilities, and a robust regulatory framework. The United States, in particular, accounts for a significant share due to high healthcare expenditure, a strong emphasis on innovation, and an aging population prone to neurological disorders. Additionally, favorable reimbursement policies and a well-established infrastructure for clinical trials support market growth.

The region is also witnessing increased investments in neurological research, which fosters the development of new therapeutic modalities. While Europe and Asia-Pacific are emerging markets with growing demand, North America's established healthcare ecosystem continues to set the pace, making it a focal point for both existing players and new entrants looking to innovate in intracranial therapeutic delivery.

Intracranial Therapeutic Delivery Market- Competitive Landscape:

The intracranial therapeutic delivery market is characterized by intense competition among established players and emerging biotech firms. Key companies like Medtronic and AbbVie dominate with their extensive product portfolios and robust R&D capabilities, focusing on advanced drug delivery systems and innovative therapies for neurological conditions. Additionally, Stryker and Boston Scientific leverage their strong presence in surgical devices to enhance therapeutic outcomes.

Emerging players, such as NeuroRx and Zynerba Pharmaceuticals, are introducing novel treatment modalities, including cannabinoid-based therapies, which diversify the market landscape. Collaboration and strategic partnerships are common as companies seek to accelerate innovation and expand their market reach. Regulatory challenges and the need for clinical validation remain critical hurdles, influencing competitive strategies. Overall, the market is poised for growth as advancements in technology and a deeper understanding of neurological diseases drive new product development.

Recent Developments:

In September 2024, CereVasc's endovascular device has the potential to serve as a novel delivery system for gene therapy directly to the brain, improving treatment efficacy for neurological conditions. By utilizing this approach, aims to enhance targeted therapy while minimizing invasiveness and side effects associated with traditional methods.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Medtronic
  • AbbVie
  • Stryker Corporation
  • Baxter International
  • Ipsen S.A.
  • Johnson & Johnson (Ethicon)
  • NuVasive
  • NeuroRx
  • CureVac AG
  • Boston Scientific
  • Aesculap
  • Zynerba Pharmaceuticals
  • Elekta
  • Intra-Cellular Therapies

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Cell-based Therapy
  • Gene Therapy
  • Enzyme Replacement Therapy

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Spinal Muscular Atrophy (SMA)
  • Multiple Sclerosis
  • Batten Disease
  • Amyotrophic Lateral Sclerosis
  • Others

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Intracranial Therapeutic Delivery Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Intracranial Therapeutic Delivery Market Snippet by Therapy
    • 2.1.2. Intracranial Therapeutic Delivery Market Snippet by Indication
    • 2.1.3. Intracranial Therapeutic Delivery Market Snippet by Country
    • 2.1.4. Intracranial Therapeutic Delivery Market Snippet by Region
  • 2.2. Competitive Insights

3. Intracranial Therapeutic Delivery Key Market Trends

  • 3.1. Intracranial Therapeutic Delivery Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Intracranial Therapeutic Delivery Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Intracranial Therapeutic Delivery Market Opportunities
  • 3.4. Intracranial Therapeutic Delivery Market Future Trends

4. Intracranial Therapeutic Delivery Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Intracranial Therapeutic Delivery Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Intracranial Therapeutic Delivery Market Landscape

  • 6.1. Intracranial Therapeutic Delivery Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Intracranial Therapeutic Delivery Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2023 & 2032 (%)
    • 7.1.2. Cell-based Therapy
    • 7.1.3. Gene Therapy
    • 7.1.4. Enzyme Replacement Therapy

8. Intracranial Therapeutic Delivery Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Spinal Muscular Atrophy (SMA)
    • 8.1.3. Multiple Sclerosis
    • 8.1.4. Batten Disease
    • 8.1.5. Amyotrophic Lateral Sclerosis
    • 8.1.6. Others

9. Intracranial Therapeutic Delivery Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Intracranial Therapeutic Delivery Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Intracranial Therapeutic Delivery Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Intracranial Therapeutic Delivery Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Intracranial Therapeutic Delivery Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Intracranial Therapeutic Delivery Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Intracranial Therapeutic Delivery Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Medtronic
    • 10.2.2. AbbVie
    • 10.2.3. Stryker Corporation
    • 10.2.4. Baxter International
    • 10.2.5. Ipsen S.A.
    • 10.2.6. Johnson & Johnson (Ethicon)
    • 10.2.7. NuVasive
    • 10.2.8. NeuroRx
    • 10.2.9. CureVac AG
    • 10.2.10. Boston Scientific
    • 10.2.11. Aesculap
    • 10.2.12. Zynerba Pharmaceuticals
    • 10.2.13. Elekta
    • 10.2.14. Intra-Cellular Therapies

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제